These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells. Molnár E; Rittler D; Baranyi M; Grusch M; Berger W; Döme B; Tóvári J; Aigner C; Tímár J; Garay T; Hegedűs B BMC Cancer; 2018 May; 18(1):542. PubMed ID: 29739364 [TBL] [Abstract][Full Text] [Related]
8. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307 [TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells. Chen Y; Xiao X; Hu G; Liu R; Xue J J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926 [TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors. Ming Z; Lim SY; Kefford RF; Rizos H Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489 [TBL] [Abstract][Full Text] [Related]
11. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
12. Modulation of Brahma expression by the mitogen-activated protein kinase/extracellular signal regulated kinase pathway is associated with changes in melanoma proliferation. Mehrotra A; Saladi SV; Trivedi AR; Aras S; Qi H; Jayanthy A; Setaluri V; de la Serna IL Arch Biochem Biophys; 2014 Dec; 563():125-35. PubMed ID: 25026375 [TBL] [Abstract][Full Text] [Related]
13. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of Dabrafenib and Trametinib in a Patient with Squamous-Cell Carcinoma, with Mutation p.D594G in Grenda A; Krawczyk P; Targowska-Duda KM; Kieszko R; Paśnik I; Milanowski J Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674722 [TBL] [Abstract][Full Text] [Related]
15. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
16. Loss of Spry1 reduces growth of BRAF Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628 [TBL] [Abstract][Full Text] [Related]
17. Identification of cell type-specific correlations between ERK activity and cell viability upon treatment with ERK1/2 inhibitors. Lebedev TD; Khabusheva ER; Mareeva SR; Ivanenko KA; Morozov AV; Spirin PV; Rubtsov PM; Snezhkina AV; Kudryavtseva AV; Sorokin MI; Buzdin AA; Prassolov VS J Biol Chem; 2022 Aug; 298(8):102226. PubMed ID: 35787369 [TBL] [Abstract][Full Text] [Related]
19. Plasma proteome alterations by MAPK inhibitors in BRAF Babačić H; Eriksson H; Pernemalm M Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984 [TBL] [Abstract][Full Text] [Related]
20. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]